Figure 1.

In vitro production of palivizumab from rAAV2/8 and rSIV.F/HN. HEK293T cells were (A) transfected with rAAV and rSIV vector genomes expressing palivizumab or GLux, were (B) transduced with rAAV and rSIV vector particles expressing palivizumab or remained naïve to treatment; 48 h post-transfection/transduction, palivizumab levels in tissue culture supernatant was measured using a Human IgG ELISA. In several cases the errors are obscured by the mean bar, where appropriate, only positive error bars are shown. The dotted line represents the limit of detection (LOD). Differences between treatment and naïve control groups were evaluated using the Kruskal–Wallis test with Dunn’s post hoc multiple comparison test.